COVID-19 vaccines cut mortality with heart failure
Jun 16, 2022
Those who are partially vaccinated and unvaccinated face the same increased risk, whereas boosted and fully vaccinated adults fare best.
Vaccine effectiveness against SARS-CoV-2 infection wanes over time
Jun 14, 2022
However, for all ages, vaccine effectiveness against severe COVID-19 was high overall, at 90% five months or longer after two doses.
Low risk seen for second allergic reaction to mRNA COVID-19 vaccine
Feb 22, 2022
Of 1,366 patients with an immediate allergic reaction to the first dose, six developed a severe immediate allergic reaction after the second dose.
Vaccination offers partial protection for postacute phase of COVID-19
May 31, 2022
Individuals with breakthrough infection have an increased risk for death and postacute sequelae compared with contemporary controls.
No increase seen in CV events in elderly after BNT162b2 vaccination
Dec 10, 2021
No increase was seen in the incidence of myocardial infarction, stroke or pulmonary embolism among those aged 75 years or older in France.
Early effectiveness assessed for fourth dose of BNT162b2 vaccine
Apr 21, 2022
The difference in absolute risk for three versus four doses was 180.1 and 68.8 cases per 100,000 for COVID-19-related hospitalization and severe COVID-19.
Fourth dose of BNT162b2 offers protection against severe COVID-19
Apr 08, 2022
Protection against COVID-19 did not wane in six weeks after receipt of fourth dose of the Pfizer–BioNTech vaccine; protection against the infection waned.
mRNA vaccines effectively prevent SARS-CoV-2 in adults in real-world setting
Jul 01, 2021
For those with SARS-CoV-2 infection, vaccinated participants had a lower mean viral load, risk of febrile symptoms and illness duration.
Fourth dose of BNT162b2 prevents severe COVID-19 in nursing home residents
Jun 27, 2022
Substantial protection against hospitalizations and deaths seen among nursing home residents during the omicron surge.
Risk for breakthrough SARS-CoV-2 infection lower with mRNA-1273
Feb 02, 2022
The risk for breakthrough infection and of 60-day hospitalization was significantly lower for mRNA-1273 (Moderna) versus BNT162b2 (Pfizer-BioNTech) vaccination.